-+ 0.00%
-+ 0.00%
-+ 0.00%

Dogwood Therapeutics says FDA accepts IND for SP16 chemotherapy-induced neuropathy trial

PUBT·04/15/2026 13:02:16
Listen to the news
Dogwood Therapeutics says FDA accepts IND for SP16 chemotherapy-induced neuropathy trial
  • Dogwood Therapeutics reported FDA acceptance of an IND for SP16 in chemotherapy-induced pain and peripheral neuropathy.
  • Serpin Pharma received a USD 2.5 million National Cancer Institute grant to fully fund SP16 Phase 1b trial.
  • Patient enrollment expected to start mid-2026 at University of Virginia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604150900PRIMZONEFULLFEED9689998) on April 15, 2026, and is solely responsible for the information contained therein.